BioSpace News Archive

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center (“Cleveland VA”) have enrolled their first patient in a Department of Defense (“DoD”) funded study of its EsoGuard® Esophageal DNA Test.

Palisade Bio, Inc. announced that of Palisade Bio, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28–30, 2022.

RenovaCare, Inc., a clinical-stage developer of patented technologies for isolating and spraying cells for the regeneration of skin and other organs and tissues, announced reductions in its management team to further streamline administrative expenses.

Can-Fite BioPharma Ltd. today announced financial results for the year ended December 31, 2021.

Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021.

Stereotaxis announces that Poland’s National Institute of Cardiology, the leading clinical center of cardiology and cardiac surgery in Warsaw, has established the first robotic electrophysiology program in the country with Stereotaxis’ Genesis Robotic Magnetic Navigation system.

Surgalign Holdings, Inc. (NASDAQ: SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the publication of results from EVoluSIon (EVSI), a large, prospective, multi-center study of clinical outcomes following minimally invasive sacroiliac joint (SIJ) fusion with decortication.

INVO Bioscience, Inc. is exhibiting the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa.

Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced that five data abstracts for ILUMYA will be presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, taking place March 25-29.